“SC”的搜索结果，显示 1-10 项，共有 2700 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

2. 肾病和高血压- 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

5. 肾病和高血压- 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

6. 肾病和高血压- 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

7. 肾病和高血压- 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

8. 肾病和高血压- 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...